BioTech
Young boy dies in trial for Pfizer Duchenne gene therapy
A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.
The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.
Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.
Get unlimited access to award-winning journalism and exclusive events.
